Sandoz Slams ‘Desperate’ J&J Attempt To Block US Private-Label Stelara Rival

Provides Update On Expectations For Samsung Bioepis-Partnered Pyzchiva Biosimilar

 
• By Dave Wallace
  
J&J is seeking to block a private-label ustekinumab biosimilar (Shutterstock)

More from Biosimilars

More from Policy & Regulation